+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nitrogen-13"

Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User - Product Thumbnail Image

Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User

  • Report
  • March 2023
  • 185 Pages
  • Global
From
Radiopharmaceuticals Market By Radioisotope, By Application, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Thumbnail Image

Radiopharmaceuticals Market By Radioisotope, By Application, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • April 2023
  • 300 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Nitrogen-13 (N-13) is a radioactive isotope of nitrogen used in Nuclear Medicine and Radiopharmacology. It is produced in a cyclotron by bombarding nitrogen gas with protons. N-13 is used in positron emission tomography (PET) imaging to diagnose and monitor diseases such as cancer, heart disease, and neurological disorders. It is also used in research to study the metabolism of drugs and other compounds. N-13 is available in a variety of forms, including solutions, kits, and kits with radiopharmaceuticals. It is typically supplied in vials or syringes, and is administered intravenously or orally. The half-life of N-13 is approximately 10 minutes, making it ideal for short-term imaging studies. Companies in the N-13 market include GE Healthcare, Bracco Diagnostics, Mallinckrodt Pharmaceuticals, and Jubilant DraxImage. Show Less Read more